Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07005297 | Clinical Genetics Branch Eligibility Screening Survey | not yet recruiting | — | 1,000 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07841925 | A Study of BL-M08D in Patients With Locally Advanced or Metastatic Melanoma and Other Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 30 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07838974 | Adding Anakinra and Tocilizumab to Nivolumab and Ipilimumab for the Treatment of Melanoma Patients 50 Years of Age or Older | not yet recruiting | Phase 1 | 40 | University of Southern CaliforniaOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07836712 | Multiple Adjunct Therapies to Improve Immunotherapy Treatment in Patients With Locally Advanced or Metastatic Melanoma or Advanced Hepatocellular Cancer | not yet recruiting | Phase 2 | 46 | University of Southern CaliforniaOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07576725 | Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial | not yet recruiting | Phase 2 | 50 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07819474 | Optimizing Tumor-Infiltrating Lymphocyte (TIL) Harvest Site and Patient Selection With CD8-PET Imaging in Patients With | not yet recruiting | N/A | 6 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07820033 | Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer: A Randomized Controlled Trial(PEARL RCT) | not yet recruiting | Phase 2 | 46 | University Health Network, TorontoOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07817901 | Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Combination Therapy With Pembrolizumab and Irinotecan in Patients With Metastatic or Recurrent Malignant Melanoma | not yet recruiting | Phase 1 / Phase 2 | 46 | Yonsei UniversityOTHER | 0 | Sep 14, 2026 | clinicaltrials |
| NCT07527325 | Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma | not yet recruiting | Phase 2 | 35 | University of California, IrvineOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07815574 | iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma(SCOPE Plus) | not yet recruiting | Phase 3 | 550 | Scancell LtdINDUSTRY | 2 | Sep 11, 2026 | clinicaltrials |
| NCT07815873 | Gut Microbiome in Patients With Lung and Melanoma Cancer and Intestinal Microbiota in Gynecologic Cancers(CERBERO) | not yet recruiting | N/A | 360 | European Institute of OncologyOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05903937 | Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases(HAITILS-PHP) | not yet recruiting | Phase 1 | 6 | Vastra Gotaland RegionOTHER_GOV | 0 | Sep 9, 2026 | clinicaltrials |
| NCT07183852 | Locoregional or Systemic Administration of Autologous Tumor Infiltrating Lymphocytes in Patients With Metastatic Melanoma(GoTIL-01) | not yet recruiting | Phase 1 | 18 | Vastra Gotaland RegionOTHER_GOV | 0 | Sep 9, 2026 | clinicaltrials |
| NCT07807878 | Trial of Temozolomide in BAP1 Mutated Patients With Advanced or Metastatic Cutaneous Melanoma(BAP1treat) | not yet recruiting | Phase 2 | 28 | Assistance Publique Hopitaux De MarseilleOTHER | 0 | Sep 8, 2026 | clinicaltrials |
| NCT07552597 | Superparamagnetic Iron Oxide for Sentinel Lymph Node Localization in Patients With Cutaneous Melanoma: MagMen-II(MagMen-II) | not yet recruiting | Phase 3 | 254 | Vastra Gotaland RegionOTHER_GOV | 0 | Sep 3, 2026 | clinicaltrials |
| NCT07803562 | Low Dose Dexamethasone for the Prevention of Cytokine Release Syndrome Associated With Tebentafusp(LODEXA) | not yet recruiting | Phase 2 | 34 | University of California, San DiegoOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07794501 | Markers of Efficacy to Immunotherapy in Patients With Metastatic Melanoma(PREMIO) | not yet recruiting | — | 200 | European Institute of OncologyOTHER | 0 | Aug 31, 2026 | clinicaltrials |
| NCT06739226 | Combination Immunotherapy Targeting Melanoma | not yet recruiting | Phase 1 / Phase 2 | 30 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07720726 | Impact of Dysport on PMFF Donor Scar | not yet recruiting | Phase 4 | 50 | Vanderbilt University Medical CenterOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07414979 | Phase 1 Study Of Intrathecal Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells For Patients With Leptomeningeal Melanoma | not yet recruiting | Phase 1 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07459543 | A Study to Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Unresectable or Metastatic Melanoma Participants In India | not yet recruiting | Phase 4 | 40 | Bristol-Myers SquibbINDUSTRY | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07740941 | NeoAdjuvant, Spare-Adjuvant (NASA) in Stage IIIB-IV (M1a) Melanoma | not yet recruiting | Phase 2 | 55 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07747935 | Study of Neoadjuvant RBP-01 In Patients With Primary Uveal Melanoma(Uveal Melanoma) | not yet recruiting | Phase 1 / Phase 2 | 30 | ReBio PharmaINDUSTRY | 0 | Aug 5, 2026 | clinicaltrials |
| NCT07689812 | A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.(SIGNAL-IO 301) | not yet recruiting | N/A | 920 | Natera, Inc.INDUSTRY | 0 | Aug 4, 2026 | clinicaltrials |
| NCT07740642 | A Comparative Usability Study of Two Total Body Skin Imaging Systems | not yet recruiting | N/A | 60 | University Hospital, Basel, SwitzerlandOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07574047 | MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma. | not yet recruiting | Phase 2 | 108 | Swiss Cancer InstituteOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07389525 | Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study | not yet recruiting | Early Phase 1 | 80 | Indiana UniversityOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07631325 | Axelopran and Nivolumab in PD-1-Refractory Metastatic Melanoma(MORALE-MM) | not yet recruiting | Phase 1 / Phase 2 | 28 | John KirkwoodOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07700121 | PICSTAT Pilot Study for CD8 PET/CT-Guided Lifileucel Treatment in Advanced Melanoma(PICSTAT) | not yet recruiting | Early Phase 1 | 10 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT05004792 | Dermoscopy Augmented Histology Trial, a Randomized Controlled Trial(DAHT-RCT) | not yet recruiting | N/A | 258 | Herlev HospitalOTHER | 0 | Jun 25, 2026 | clinicaltrials |
| NCT07529080 | Personalized Cancer Support (Thrive Track) to Manage the Emotional Needs of Young Adults With Thyroid, Melanoma and Testicular Cancer, PerCS-YA Trial | not yet recruiting | N/A | 142 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07662694 | CLASSIFY-OMM: Multicenter Rare Disease Cohort for T-Stage Reclassification and Molecular Subtyping-Based Precision Therapy in Oral Mucosal Melanoma(CLASSIFY-OMM) | not yet recruiting | — | 1,100 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07660666 | Feasibility of an Enhanced Symptom Monitoring and Expedited Subspecialty Care Referral Intervention to Improve Side Effect Management for Patients With Melanoma Receiving an Immune Checkpoint Inhibitor | not yet recruiting | N/A | 50 | OHSU Knight Cancer InstituteOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT07653087 | Evaluating a Decision Aid for Sentinel Lymph Node Biopsy in Intermediate-Risk Melanoma(Mel73) | not yet recruiting | N/A | 66 | University of VirginiaOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT07651618 | A Phase II Trial of Tumour Infiltrating Lymphocyte Adoptive Cell Therapy in Patients With Immune Checkpoint Inhibitor Resistant Unresectable or Metastatic Melanoma(PERTIL-01) | not yet recruiting | Phase 2 | 10 | East Metropolitan Health Service, AustraliaOTHER_GOV | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07628894 | Circadian-Optimized Light Therapy for the Treatment of Patients With Advanced Melanoma Receiving Tumor-Infiltrating Lymphocyte Therapy | not yet recruiting | Phase 1 | 8 | City of Hope Medical CenterOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT07619898 | PHOENIX-ECP- Extracorporeal Photopheresis for Immune-related Colitis and/or Hepatitis in Advanced Melanoma With Inadequate Response to Steroid Exposure(PHOENIX-ECP) | not yet recruiting | Phase 2 | 112 | Therakos LLCINDUSTRY | 0 | Jun 2, 2026 | clinicaltrials |
| NCT07615881 | Comparing Intravenous or Intradermal Administration of Anti-CTLA-4 in Combination With Anti-PD1 Treatment in Patients With Melanoma(IpiD) | not yet recruiting | Phase 1 / Phase 2 | 18 | Amsterdam UMC, location VUmcOTHER | 0 | May 29, 2026 | clinicaltrials |
| NCT07581509 | Pharmacokinetics, Safety, and Immunogenicity of Bmab1800 and Keytruda® as Adjuvant Monotherapy in Patients With Melanoma | not yet recruiting | Phase 1 | 138 | Biocon Biologics UK PLCINDUSTRY | 0 | May 14, 2026 | clinicaltrials |
| NCT07444606 | Dose Ranging, Toxicity Seeking, Phase 1 Trial of Oncolytic Adenoviral Therapy for Melanoma Intracranial and Extracranial Metastases | not yet recruiting | Phase 1 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT07517653 | Neoadjuvant SHR-1701 Plus Famitinib With Response-guided Adjuvant Therapy in Resectable Mucosal Melanoma | not yet recruiting | Phase 2 | 70 | Shanghai Zhongshan HospitalOTHER | 0 | Apr 8, 2026 | clinicaltrials |
| NCT07511036 | PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable Melanoma | not yet recruiting | Phase 2 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07501104 | Neoadjuvant Pucotenlimab Combined With Lenvatinib and Temozolomide in Resectable Stage IIB/III Acral Melanoma(TRIUMPH-AM) | not yet recruiting | Phase 2 | 30 | Shanghai Zhongshan HospitalOTHER | 0 | Mar 30, 2026 | clinicaltrials |
| NCT07492121 | Screening for Brain Metastases(GAPIMET) | not yet recruiting | Phase 2 | 180 | University of ZurichOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT06708455 | Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma | not yet recruiting | Phase 2 | 65 | Rapa Therapeutics LLCINDUSTRY | 1 | Mar 19, 2026 | clinicaltrials |
| NCT07442292 | PD-L1 Targeting Peptide Probe for PET Imaging of Solid Tumor | not yet recruiting | — | 40 | Peking University Cancer Hospital & InstituteOTHER | 0 | Mar 5, 2026 | clinicaltrials |
| NCT07437300 | Influence of a High-fiber Diet on the Microbiota and the Response to Immunotherapy in Patients Treated for Melanoma.(FIBIOME) | not yet recruiting | — | 60 | University Hospital, GrenobleOTHER | 0 | Feb 27, 2026 | clinicaltrials |
| NCT07406724 | HS-IT101 Injection Versus Chemotherapy in the Treatment of Advanced Melanoma | not yet recruiting | Phase 2 | 90 | Qingdao Sino-Cell Biomedicine Co., Ltd.INDUSTRY | 0 | Feb 12, 2026 | clinicaltrials |
| NCT07376512 | Predicting Response to Anti-PD-1/PD-L1 Immunotherapy by Plasma Extracellular Vesicle Analysis(EVpredict) | not yet recruiting | — | 378 | Centre Georges Francois LeclercOTHER | 1 | Jan 29, 2026 | clinicaltrials |
Data updated 14 hours agoSource updated Sep 29, 2026source: clinicaltrials